Dry Powder Inhalers: Key Considerations for Combination Product Development
June 24, 2020
Dry powder inhalers (DPIs) are an important delivery technology for inhaled medicines in both respiratory and non-respiratory disease areas. Andreas Meliniotis, director of device development at Vectura, helps navigate the complex area of DPI product development and highlights the key considerations for both novel- and generic-drug programs.
Live: Wednesday, Jun. 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST
On demand available after final airing Jun. 24, 2021